Glymbasi is a drug designed from empagliflozin and linagliptin, two well-known and used antidiabetic drugs used to treat type-2 diabetes. This newly designed drug combines the two mechanisms of these drugs to co-administer simultaneous glycemic control on all fronts to provide a more effective and efficient treatment for type 2 diabetics . Glyxambi was created by combining appropriate dosages of emagliflozin and linagliptin into a single tablet for once daily use. This drug is now available for physicians to administer to their patients because companies such as BIPI and Eli Lilly have pooled their resources to provide more effective treatment options for this disease
